Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Conclusion: EMD 1201081 was well tolerated combined with cetuximab, but there was no incremental clinical efficacy.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Dermatitis | Dermatology | Drugs & Pharmacology | Erbitux | Investigational New Drugs | Respiratory Medicine | Skin Cancer | Squamous Cell Carcinoma | Study